Achieve Life Sciences Q2 2026: $74.8M Loss, CRL Delays Cytisinicline Approval, Cash Runway Extended
ACHV has more than doubled off its 52-week low of $2.371.
Summary
Achieve Life Sciences' Q2 2026 10-Q reveals a $74.8M net loss, an FDA Complete Response Letter delaying cytisinicline approval, and a new arbitration demand from Sopharma. Cash reserves of $187.3M provide runway, but the CRL pushes the approval timeline into 2027.
Key Events · Earnings and Guidance · ACHV
-
FDA Issues Complete Response Letter
In June 2026, the FDA issued a CRL for cytisinicline, citing manufacturing deficiencies at a third-party facility. No clinical safety or efficacy issues were identified. The company plans to resubmit the NDA in Q4 2026 with new manufacturer Adare, targeting potential approval in H1 2027.
-
Q2 Net Loss of $74.8M
The net loss of $74.8M includes a $48.7M non-cash warrant liability fair-value adjustment—a paper loss driven by the stock price increase, not a cash outflow. Operating expenses rose to $18.4M, driven by higher G&A from stock-based compensation and commercial preparation.
-
Cash Position of $187.3M
Cash, cash equivalents, and marketable securities totaled $187.3M as of June 30, 2026, following the $168.2M net proceeds from the April 2026 private placement. Negative working capital of $9.4M reflects the large warrant liability classified as current.
-
Sopharma Arbitration Demand
In July 2026, Sopharma filed an arbitration demand alleging breach of the supply agreement. Achieve disputes the claims and intends to defend vigorously. No liability has been recorded as of June 30, 2026.
Analysis · ACHV · Life Sciences
A $48.7 million non-cash warrant liability remeasurement—a paper loss reflecting the stock's rise, not a cash outflow—drove Achieve Life Sciences' Q2 net loss to $74.8 million. The more consequential development is the FDA's Complete Response Letter (CRL) for cytisinicline, received in June 2026, which delays the smoking cessation drug's approval due to manufacturing deficiencies at a third-party facility. Management plans to resubmit the NDA in Q4 2026 with a new manufacturer, Adare, targeting potential approval in H1 2027. Cash and equivalents stand at $187.3 million, providing runway but with a negative working capital of $9.4 million. Separately, Sopharma filed an arbitration demand in July 2026, alleging breach of the supply agreement—a legal overhang. The authorized share count was subsequently increased to 300 million, enabling future financings or warrant exercises.
At the time of this filing, ACHV was trading at $6.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $695M. The 52-week trading range was $2.37 to $7.11. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.